VanEck Associates’s Royalty Pharma RPRX Stock Holding History

VanEck Associates’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.68M	Sell	101,292 -37,767	-27%	-$1.97M	﹤0.01%	803
2026 Q1	$6.67M	Sell	139,059 -24,991	-15%	-$1.09M	0.01%	716
2025 Q4	$6.34M	Sell	164,050 -12,570	-7%	-$479K	0.01%	715
2025 Q3	$6.23M	Sell	176,620 -19,904	-10%	-$721K	0.01%	689
2025 Q2	$7.08M	Buy	196,524 +72,499	+58%	+$2.4M	0.01%	593
2025 Q1	$3.86M	Sell	124,025 -3,115	-2%	-$98.7K	0.01%	810
2024 Q4	$3.24M	Buy	127,140 +25,640	+25%	+$680K	﹤0.01%	843
2024 Q3	$2.78M	Buy	101,500 +64,057	+171%	+$1.77M	﹤0.01%	842
2024 Q2	$988K	Buy	37,443 +1,980	+6%	+$54.9K	﹤0.01%	995
2024 Q1	$1.08M	Buy	35,463 +28,987	+448%	+$855K	﹤0.01%	974
2023 Q4	$182K	Buy	6,476 +2,944	+83%	+$80.9K	﹤0.01%	1176
2023 Q3	$96K	Buy	3,532 +309	+10%	+$9.18K	﹤0.01%	1233
2023 Q2	$99K	Buy	+3,223	New	+$109K	﹤0.01%	1244

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

VanEck Associates's RPRX Position: Q2 2026 in Review

VanEck Associates reduced its Royalty Pharma (RPRX) stake by 27% in Q2 2026, selling an estimated $1.97M and leaving 101,292 shares worth $5.68M. The position accounts for ﹤0.01% of the portfolio, ranked #803.

VanEck Associates first reported a position in RPRX in Q2 2023 and has held it in 13 quarters since. The position peaked at $7.08M in Q2 2025. 643 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

VanEck Associates held 101,292 shares of Royalty Pharma worth $5.68M as of Q2 2026.
VanEck Associates sold 37,767 Royalty Pharma shares in Q2 2026, an estimated $1.97M.
Royalty Pharma made up ﹤0.01% of VanEck Associates's portfolio in Q2 2026, its #803 holding.
VanEck Associates first reported a position in Royalty Pharma in Q2 2023 and has held it in 13 quarters since.
VanEck Associates's Royalty Pharma position peaked at $7.08M in Q2 2025.
643 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on VanEck Associates's 13F filing for Q2 2026, filed 14 Aug 2026.